Fabio Bardanzellu

Abstract 4653: Platelet to lymphocyte ratio and platelet count: new frontiers as prognostic factors in metastatic colorectal cancer patients receiving anti-angiogenic drugs

Francesco Loi, Enrico Palmas, Claudia Codipietro, Andrea Pretta et autres

Background: Anti-angiogenic drugs represent a milestone of metastatic colorectal cancer (mCRC) pts) treatment. To date, no validated prognostic biomarkers are available. Recently, hematological parameters became of particular interest in solid tumors, including mcRC. Here, we present the results of our research in …

it (code pays fourni par la source)

TP53 mutation as predictive factor of platinum response in BRCA-mutated ovarian cancer: A prospective case-series analysis.

Eleonora Lai, Manuela Neri, E. Sanna, Sonia Nemolato et autres

128 Background: Platinum sensitivity (PS) is a prerequisite for first-line PARP inhibitors (PARPi) in locally advanced and relapsed high grade serous ovarian cancer (HGS-OC). BRCA mutations are predictive of PS and of response to PARPi. Notably, platinum and PARPi cytotoxic action is …

it (code pays fourni par la source)

Abstract A020: TP53 mutation and prediction of platinum response in BRCA-mutated ovarian cancer: A prospective case-series analysis

Eleonora Lai, Manuela Neri, E. Sanna, Sonia Nemolato et autres

Abstract Background and aim of the study: Currently, platinum sensitivity (PS) is a prerequisite for first-line PARP inhibitors (PARPi) in locally advanced and relapsed high grade serous ovarian cancer (HGS-OC). BRCA mutations are recognized as predictive of PS and, therefore, of response …

it (code pays fourni par la source)

CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety

Demi Wekking, Matteo Lambertini, Mariele Dessì, Nerina Denaro et autres

The development of oral cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib, has revolutionized the treatment landscape for patients with hormone-receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (BC). When combined with an …

nl, it (code pays fourni par la source)

Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score

Pina Ziranu, Paolo Albino Ferrari, Francesco Guerrera, Pietro Bertoglio et autres

it, gb (code pays fourni par la source)

Preoperative assessment in lung-limited metastatic patients with colorectal cancer: The Meta-Lung Score.

Pina Ziranu, Paolo Albino Ferrari, Francesco Guerrera, Pietro Bertoglio et autres

3598 Background: Due to the inconsistent data on curative resection of isolated lung metastases (LM) from colorectal cancer (CRC) and the lack of specific recommendations, the therapeutic approaches for metastatic liver disease are mostly applied to LM treatment, despite differences in their …

it, gb (code pays fourni par la source)

Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma.

Andrea Pretta, Pina Ziranu, Clelia Donisi, Giovanna Pinna et autres

e15593 Background: Hypothyroidism is the most common thyroid disorder and levothyroxine is the mainstay treatment. Levothyroxine is mainly used to restore the euthyroid clinical and biochemical status in the gland. Recent literature has correlated chronic hormonal treatment with adverse effects on bone …

it (code pays fourni par la source)

CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors

Pina Ziranu, Andrea Pretta, Marta Pozzari, Antonio Maccioni et autres

Immune checkpoint inhibitors (ICIs) showed efficacy in metastatic colorectal cancer (mCRC) with mismatch-repair deficiency or high microsatellite instability (dMMR-MSI-H). Unfortunately, a patient's subgroup did not benefit from immunotherapy. Caudal-related homeobox transcription factor 2 (CDX-2) would seem to influence immunotherapy's sensitivity, promoting the …

it (code pays fourni par la source)

Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?

Chiara Tommasi, Rita Balsano, Matilde Corianò, Benedetta Pellegrino et autres

Breast cancer is still a lethal disease and the leading cause of death in women, undermining patients' survival and quality of life. Modern techniques of surgery and radiotherapy allow for the obtaining of good results in terms of survival, however they cause …

it (code pays fourni par la source)

CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors

Pina Ziranu, Andrea Pretta, Marta Pozzari, Antonio Maccioni et autres

it, us (code pays fourni par la source)

CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors

Pina Ziranu, Andrea Pretta, Marta Pozzari, Antonio Maccioni et autres

it, us (code pays fourni par la source)

Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma.

Andrea Pretta, Erika Cimbro, Riccardo Giampieri, Dario Spanu et autres

e16301 Background: The association between pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus (DM2) has long been evaluated. Indeed, DM2 can be both an epiphenomenon of PDAC and a risk factor. However, the data on the influence of DM2 and concomitant …

it (code pays fourni par la source)